Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Chemours Company (CC) Tanks After Company Discloses Internal Investigation and Delays Earnings Release - Hagens Berman

CC

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages CC Investors Who Suffered Substantial Losses to Contact Firm's Attorneys Investigating Possible Securities Law Violations

San Francisco, California--(Newsfile Corp. - February 28, 2024) - Hagens Berman urges The Chemours Company (NYSE: CC) investors who suffered substantial losses to submit your losses now.

Visit: www.hbsslaw.com/investor-fraud/CC
Contact An Attorney Now: CC@hbsslaw.com
844-916-0895

The Chemours Company (NYSE: CC) Investigation:

"We're investigating whether Chemours may have misrepresented or failed to disclose material facts concerning its internal controls over financial reporting," said Reed Kathrein, the Hagens Berman partner leading the investigation.

Specifically, on Feb. 13, 2024 Chemours announced that it postponed the release of its financial results and conference call related to its Q4 and FYE Dec. 31, 2023. The company revealed that it "is evaluating its internal control over financial reporting as of December 31, 2023 with respect to maintaining effective controls related to information and communications." The company also revealed that its "Audit Committee also needs additional time to complete a related internal review."

This news drove the price of Chemours shares down $3.85, or down almost 13%, on Feb. 14, 2024.

If you invested in The Chemours Company and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now »

If you'd like more information and answers to frequently asked questions about the Chemours investigation, read more »

Whistleblowers: Persons with non-public information regarding The Chemours Company should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email CC@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.

Contact:
Reed Kathrein, 844-916-0895

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/199676

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today